MedPath

Quantification and technique development to reduce ano-rectal toxicity in prostate radiotherapy.

Recruiting
Conditions
prostate cancer
prostate carcinoma
10038588
10036958
Registration Number
NL-OMON33176
Lead Sponsor
niversitair Medisch Centrum Sint Radboud
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Biopsy proven prostate carcinoma.
Localized prostate carcinoma (cT1-3N0M0)
Written informed consent.

Exclusion Criteria

Previous treatment for this tumour, other than neo-adjuvant androgen suppression therapy.
Distant metastases
Contra-indications for radiotherapy (Morbus Crohn, ulcerative colitis, severe diverticulitis.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Subjective complaints, based on questionnaires.<br /><br>Anal pressures and rectal compliance.<br /><br>Amount and severity of telangiectasias to the rectal and sigmoid mucosa.<br /><br><br /><br>In addition, the course of these parameters over 2 years and their correlation,<br /><br>and the correlation to the doses to the rectum and anal canal. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Not applicable.</p><br>
© Copyright 2025. All Rights Reserved by MedPath